Vivos TherapeuticsVVOS -7.67%43 Debt-to-EBITDA is -0.50 as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 43/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 212765.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vivos Therapeutics's Debt-to-EBITDA or its related term are showing as below:
VVOS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.73 Med: -0.12 Max: -0.08
Current: -0.58
During the past 8 years, the highest Debt-to-EBITDA Ratio of Vivos Therapeutics was -0.08. The lowest was -0.73. And the median was -0.12.
VVOS's Debt-to-EBITDA is ranked worse than 100% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs VVOS: -0.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vivos Therapeutics Debt-to-EBITDA Related Terms
Vivos Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVOS vs XAIR, TNON, BMRA: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Vivos Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Vivos Therapeutics (VVOS) has a Debt-to-EBITDA of -0.50 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivos Therapeutics. According to the industry distribution chart, Vivos Therapeutics ranks #999999 out of 470 companies in the Medical Devices & Instruments industry.
Is Vivos Therapeutics' Debt-to-EBITDA too high?
Vivos Therapeutics' current Debt-to-EBITDA is -0.50. Based on the distribution chart, Vivos Therapeutics ranks #999999 out of 470 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Debt-to-EBITDA compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #999999 out of 470 companies for Debt-to-EBITDA. This places Vivos Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vivos Therapeutics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Debt-to-EBITDA is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.43 — trading 62.4% below its estimated fair value. The current Debt-to-EBITDA is -0.50. Vivos Therapeutics' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Debt-to-EBITDA is -0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.43 is trading 62.4% below its estimated GF Value™ of $1.15.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Debt-to-EBITDA: -0.50
GF Value™: $1.15 vs. price of $0.43 (62.4% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
43GF Score
Get the complete analysis for VVOS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
